Refractory Angina is a rare, chronic, and progressive form of pulmonary hypertension characterized by elevated pulmonary arterial pressure (PAP) & pulmonary vascular resistance (PVR) in blood vessels carrying the blood through the lungs from the right side of the heart. It occurs due to the stiffening and tightening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction.
DelveInsight’s ‘Refractory Angina Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical & forecasted Refractory Angina epidemiology in the 7MM: The United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Key Facts of the Refractory Angina Epidemiology Report:
- DelveInsight estimates that the highest prevalence of Refractory Angina in the USA is in patients with Class III sub-type. It had more than 13,00,000 cases in 2020.
- Refractory Angina prevalence for the patients with Class IV was more than 5,00,000 cases in 2020 that is projected to increase in 2030.
- Among EU5, Germany had the highest population of Refractory Angina followed by the UK.
- According to DelveInsight’s analysis, Refractory Angina is more prominent in males in comparison to females.
- Refractory Angina prevalent population in Japan was more than 150,000 cases in 2020.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/refractory-angina-epidemiology-forecast
Refractory Angina is characterized by similar symptoms that appear during heart and lung conditions. Therefore, several techniques and blood tests such as Chest X-Ray, Blood Tests, Cardiac Catheterization, Electrocardiogram, and Echocardiogram are used for diagnosing PAH.
Cardiac Catheterization is the process that involves the insertion of a thin tube into a vein of the neck. Right heart catheterization is used for measuring the amount of pressure developed in pulmonary arteries. It is also used for assessing the functioning of the heart.
Blood tests are mostly recommended to determine the presence of connective tissue disease, Human Immunodeficiency Virus (HIV) infection, and Sickle Cell Anemia.
“Refractory Angina is classified on the basis of grading the pain. Among these sub-types, Class III contributes the major patient share of RA followed by Class IV angina.”
Request for Free Sample Report: https://www.delveinsight.com/sample-request/refractory-angina-epidemiology-forecast
Scope of the Refractory Angina Report
- Refractory Angina report covers a detailed overview of its causes, symptoms, pathophysiology, classification, diagnosis, & treatment patterns.
- Refractory Angina Epidemiology Report & Model provide an overview of the global trends and risk factors of Refractory Angina in the 7MM: The United States, France, Germany, Spain, UK, Italy, and Japan)
- The report provides insight into the historical & forecasted Refractory Angina patient pool in 7MM covering the United States, EU5 (Germany, Italy, Spain, France, UK) & Japan
- The Refractory Angina report helps to recognize the growth opportunities of Refractory Angina in the 7MM with respect to the patient population
- The Refractory Angina report assesses the risk factors, burden & highlights the unmet needs of Refractory Angina disease.
- The Refractory Angina report provides the segmentation of the Refractory Angina epidemiology.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/refractory-angina-epidemiology-forecast
Key Refractory Angina Epidemiology Questions Covered:
- What will be the market growth opportunities in the 7MM with respect to the Refractory Angina patient population?
- What are the key findings related to the Refractory Angina epidemiology across seven major markets & which country will have the highest number of Refractory Angina patients during the forecast period (2018-2030)?
- What would be the total number of Refractory Angina patients across the 7MM during the forecast period (2018-2030)?
- Among the EU5 countries, which country will have the highest number of Refractory Angina patients during the forecast period (2018-2030)?
- At what CAGR the Refractory Angina patient population is expected to grow by 7MM during the forecast period (2018-2030)?
- What are the disease risk, burden, and unmet needs of Refractory Angina?
- What are the currently Refractory Angina treatments available?
Request for Free Sample Report: https://www.delveinsight.com/sample-request/refractory-angina-epidemiology-forecast
Related Reports:
The Refractory Angina report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Refractory Angina across the complete product development cycle, including all clinical and non-clinical stages.
The Refractory Angina market report provides current treatment practices, emerging drugs, Refractory Angina market share of the individual therapies, current and forecasted Refractory Angina Market Size from 2018 to 2030 segmented by seven major markets.
Get in touch with our Business executive for Rich and Deep Healthcare Consulting Solutions
Latest Blogs:
MedTech Industry: Commercial, Regulatory and Clinical Updates
Who is Going to be a Trendsetter in the Hereditary Deafness Market?
The Rising Burden of Substance Use Disorder And The Treatment Scenario
Other Links:
- Bipolar Depression Market
- Corneal Endothelial Dystrophy Market
- Endometriosis Pain Market
- Hepatic Encephalopathy Market
- Higher-Risk Chronic Myelomonocytic Leukemia Market
- Palmar Hyperhidrosis Market
- West Syndrome Market
- Binge Eating Disorder Market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at:
Contact Information:
Ankit Nigam info@delveinsight.com +91-9650213330
Tags:
, Menafn, IPS, Reportedtimes, iCN Internal Distribution, Extended Distribution, Research Newswire, English
Contact Information:
Ankit Nigam
info@delveinsight.com
+91-9650213330
The post Refractory Angina Epidemiology Forecast: Insights into Disease Overview, Patient Pool, Prevalence, and Futuristic Outlook | DelveInsight appeared first on Financial Market Brief.